Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inetetamab, Pyrotinib, and Nab-paclitaxel in Neoadjuvant HER2-positive Breast Cancer
NCT05444998Phase 2Completed
- Sponsor
- Xijing Hospital
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inetetamab, pyrotinib, paclitaxel in breast cancer, sponsored by Xijing Hospital. Started Nov 2022; status: completed.
02
Drugs
inetetamabpyrotinibpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05444998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444998.